Modulatory potentials of the aqueous stem bark extract of Mangifera indica on carbon tetrachloride-induced hepatotoxicity in rats  by Adeneye, Adejuwon Adewale et al.
ble at ScienceDirect
Journal of Traditional and Complementary Medicine 5 (2015) 106e115Contents lists availaHOSTED BY
Journal of Traditional and Complementary Medicine
journal homepage: http : / /www.elsevier .com/locate/ j tcmeModulatory potentials of the aqueous stem bark extract of Mangifera
indica on carbon tetrachloride-induced hepatotoxicity in rats
Adejuwon Adewale Adeneye a, *, Olufunsho Awodele b, Sheriff Aboyade Aiyeola b,
Adokiye Senibo Benebo c
a Department of Pharmacology, Faculty of Medical Sciences, Lagos State University College of Medicine, 1-5 Oba Akinjobi Way, G.R.A., Ikeja, Lagos State,
Nigeria
b Department of Pharmacology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Idi-Araba, Surulere, Lagos State, Nigeria
c Department of Pathology and Forensic Medicine, Faculty of Medical Sciences, Lagos State University College of Medicine, 1-5 Oba Akinjobi Way, G.R.A.,
Ikeja, Lagos State, Nigeriaa r t i c l e i n f o
Article history:
Received 5 May 2014
Received in revised form
1 June 2014
Accepted 2 June 2014
Available online 8 January 2015
Keywords:
Mangifera indica
Stem bark
Carbon tetrachloride
Hepatoprotective
Antioxidant* Corresponding author. Tel.: þ234 802 0690 946 (
E-mail addresses: adejuwon.adeneye@lasucom.e
com (A.A. Adeneye).
Peer review under responsibility of The Center
National Taiwan University.
http://dx.doi.org/10.1016/j.jtcme.2014.11.001
2225-4110/Copyright © 2014, Center for Food and Bioa b s t r a c t
Among Yoruba herbalists (Southwest Nigeria), hot water infusion of Mangifera indica L. (芒果Mang Guǒ)
stem bark is reputedly used for the treatment of fever, jaundice and liver disorders. The present study,
therefore, investigates the protective effects andmechanism(s) of chemopreventive and curative effects of
125e500 mg/kg/day of Mangifera indica aqueous stem bark extract (MIASE) in acute CCl4-induced liver
damage in rats. Rats were treated intragastrically with 125, 250 and 500 mg/kg/day of MIASE for 7 days
before and after the administration of CCl4 (3 ml/kg of 20% CCl4, i.p.). The serum levels of alanine amino-
transferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein (TP), albumin
(ALB), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low density
lipoprotein cholesterol (LDL-c), total bilirubin (TB), conjugated bilirubin (CB) and fasting blood glucose
(FBG) levels were estimated. In addition, hepatic tissue reduced glutathione (GSH) and the malondialde-
hyde (MDA) concentrations, catalase (CAT), superoxide (SOD) activities in the hepatic homogenate, and
histopathological changes in the rat liver sectionswere determined. Preliminary qualitative phytochemical
screening for bioactive compounds inMIASE was also conducted. Results showed that oral treatment with
125e500 mg/kg/day of MIASE signiﬁcantly attenuated the increase in serum ALT, AST, ALP, FBG, TB, CB and
LDL-c levels in acute liver injury induced by CCl4 treatment. Findings also revealed signiﬁcant elevations in
the serum TC, TG, HDL-c, TP and ALB levels. There was marked architectural remodeling in the hepatic
lesions of hepatocyte vacuolation and centrilobular necrosis induced by CCl4 treatment, coupled with
signiﬁcant weight loss. MIASE also markedly enhanced SOD and CAT activities while reducing MAD for-
mation; and increased GSH concentration in the hepatic homogenate compared with untreated CCl4-
intoxicated group, with more protection offered in the curative than the chemopreventive models of CCl4
hepatotoxicity. Thus, these results indicate that MIASE has a profound protective effect against acute CCl4-
induced hepatotoxicity in rats, which may be due to its free radicals scavenging effect, inhibition of lipid
peroxidation, and its ability to increase antioxidant activity.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.Introduction
Mangifera indica L. (芒果Mang Guǒ) (family: Anarcardiaceae) tree
is among the most economically and culturally important tropicalmobile).
du.ng, adeneye2001@yahoo.
for Food and Biomolecules,
molecules, National Taiwan Univerainforest medicinal plant in Asia and Africa, especially for its edible
fruits. It is widely known as Mango. The mango tree is an erect
perennial tree with a broad rounded canopy which at full maturity
may attain up to 10e30m and 30e35 m in height and width,
respectively.1 Previous studies indicate mango possesses anti-
diabetic2e5 hypolipidemic, antioxidant, antiviral, cardiotonic, hypo-
tensive, anti-inﬂammatory and analgesic,6 antibone resorption,
antihelminthic, antispasmodic, antipyretic, antidiarrheal, anti-
allergic, gastroprotective, hepatoprotective and immunomodulatoryrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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gifera indica leaves is highly valued in the local management of
feverish and jaundiced conditions for which its antiplasmodial anti-
pyretic effects were reported.7,8
The polyphenolic glucosyl xanthones, mangiferin and vimang,
isolated from Mangifera indica have been documented to possess
strong antiviral,9,10 antioxidant,11,12 gastroprotective,13 anti-
lipoperoxidation, immunomodulatory and anticancer,14 cardiotonic
and hypotensive,15 antihelminthic and anti-allergic,16 wound
healing, antidegenerative, antidiabetic and antiatherogenic activ-
ities.17 Also reported is the hepatoprotective effect of Vimang iso-
lated fromMangifera indica on primary culture of rat hepatocytes.18
InAfrican folkmedicine,water infusions ofMangifera indica stem
bark are highly valued in the local treatment of malaria fever, diar-
rhea, diabetes mellitus and liver diseases.19 In view of its traditional
use in the local treatmentof hepatic disorders, thepresent studywas
designed at evaluating the hepatoprotective effect and mecha-
nism(s) of 125e500 mg/kg/day ofMIASE using carbon tetrachloride
(CCl4)-induced hepatotoxicity in Wistar rat model.Materials and methods
Plant collection and identiﬁcation
Fresh leaves, inﬂorescence and stem bark of Mangifera indica L.
(芒果Mang Guǒ) plant were collected from the deciduous forest of
Odo-Remo in Remo North Local Government Area of Ogun State,
Nigeria, in the month of March, 2013. Botanical identiﬁcation and
authentication was done by Mr. T. K. Odewo, Chief Taxonomist in
the Department of Botany and Microbiology, University of Lagos,
Akoka, Lagos State, Nigeria. Voucher specimenwas deposited in the
Departmental herbariumwith the reference no. LUH 5528, allotted.Preparation of the plant extract
Fresh peels of Mangifera indica stem bark were harvested and
gently washed in tap water to remove dirt. These were then
completely air-dried in the laboratory under room temperature
(24± 2 C) for 4weeks protected fromdirect heat or sunlight.When
dried, the stembarkswere thenpulverized into coarsepowderusing
Laboratory Hammer-mill of the Pharmacognosy Department, Fac-
ulty of Pharmacy, University of Lagos, Idi-Araba, Lagos, Nigeria.
40 g of the powdery form was dissolved in 400 ml of distilled
water and boiled at 100 C under continuous stirringwithmagnetic
stirrer for 2 hours. The mixture was then ﬁltered using a piece of
clean white cloth. The aqueous ﬁltrate was transferred into an
aerated oven already preset at 40 C to obtain the dried extract of
the seed; the yield was 15%.
Yield¼ weightof drycrudeextract obtainedðgÞ
weightof starting stembarkpowderextractedðgÞ100Qualitative phytochemical analyses of MIASE
Preliminary phytochemical analyses of the Mangifera indica
aqueous stem bark extract were done using standard procedure of
Sofowora.20 The procedures are summarized below:Test for tannins
Ferric chloride test: About 0.5 g of the dried powdered samples
was boiled in 20 ml of water in a test tube and then ﬁltered. A few
drops of 0.1 % ferric chloride was added and observed for brownish
green or a blueeblack coloration.Test for phlobatinnins
The plant extract solutions were boiled with 1% aqueous hy-
drochloric acid on a water bath for 5 minutes then color changes
were observed.
Test for saponin
Froth test: 2 g of the powdered sample was boiled in 20 ml of
distilled water in a water bath and then ﬁltered. 10 ml of the ﬁltrate
was mixed with 5 ml of distilled water and shaken vigorously for a
stable persistent froth. The frothing wasmixedwith 3 drops of olive
oil and shaken vigorously, then observed for formation of emulsion.
Test for ﬂavonoids
Three methods were used to determine the presence of ﬂavo-
noids in the plant samples.
a. A portion of the extract solution was in each case heat with
10 ml of ethyl acetate over a steam bath for 3 minutes. The
mixture was ﬁltered and 4 ml of ﬁltrate was shakenwith 1 ml of
dilute ammonia solution and color changes were observed.
b. Lead acetate test: To a solution of 0.5 g extract in water about
1 ml of 10% lead acetate solution was added. Production of
yellow precipitate is considered as positive for ﬂavonoids.
c. Few drops of 1% aluminum chloride solutionwas added to about
2 ml of the plant extract solutions then color changes were
observed.
Test for steroidal compound
Two methods were used to determine the presence of terpe-
noids in the Mangifera indica stem bark aqueous extract sample.
-Lieberman's test: 0.5 g of extract was dissolved in 2 ml of acidic
anhydride and cooled well in an ice. Sulfuric acid was then carefully
added. A color change from violet to blue or green in some samples
indicating the presence of steroidal nucleus (i.e. aglycone portion of
the cardiac glycoside).
Acute oral toxicity test of MIASE using preliminary dose test of up
and down procedure
The Acute oral toxicity study was conducted using the limit dose
test of up and down procedure according to OECD/OCDE Test
Guidelines on Acute Oral Toxicity under a computer-guided Sta-
tistical Programme-AOT425statPgm, version 1.0,21 at a limit dose of
5000 mg/kg body weight/oral route and default of Sigma at 0.5. A
total of three female young adult Wistar rats were systematically
selected out of a population of 10 Wistar rats (6e8 weeks old) by
systematic randomization techniques. The population sample was
selected such that theweight differences do not exceed± 10% of the
mean initial weight of the sample population. The rats were fasted
of rat chow overnight prior to dosing on each occasion. A rat was
picked at a time, weighed and dosed with equivalent 5000 mg/kg
body weight of the crude extract dissolved in 10 ml/kg of 0.9%
normal saline used as the vehicle. Feeding was done using metallic
gastric feeding tube. After the extract administration, each rat was
observed for the ﬁrst 5 minutes after oral administration for signs
of possible regurgitation and then kept in a cage for observation.
The treated rat was watched for every 15 min in the ﬁrst 4 hour
after dosing, then every 30 minutes for the successive 6 hour and
then daily for the successive 38 hour for the short-term outcome
and the remaining 12 days for the long-term possible lethal
outcome which in this case was “death”. Behavioral manifestations
of acute oral toxicity were also observed. All observations were
systematically recorded with individual records being maintained
for each rat.
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After institutional ethical clearance for the studywas obtained, a
total of eighty-four young adult Male Wistar rats aged 8e10 weeks
and with weight range of 110 ge150 g were purchased (in two
separate batches of forty-two rats in each batch) from the Labora-
tory Animal Centre of the College of Medicine, University of Lagos,
Idi-Araba, Lagos State andwere kept in the Rat Colony of the Animal
House of Lagos State University College of Medicine, Ikeja, Lagos
State, where the laboratoryworkwas carried out. On each occasion,
the rats were allowed one week of acclimatization before being
used for experimentation. The animals were housed in standard
metal cages, maintained under standard laboratory conditions and
fed standard rat pellets and potable water ad libitum.
Experimental design
Drug-induced hepatic and renal toxicity models used in the
conduct of this study was done using 30% carbon tetrachloride
dissolved in olive oil according to themodiﬁedmethod of Lu et al. 22
The study was conducted in two phases (chemopreventive and
curative) with each phase consisting of 36 male Wistar rats. The
rats in each model were grouped into six groups of six rats each -
three control and treatment groups, respectively.
Induction of CCl4-induced hepatotoxicity and oral drug treatment in
the chemopreventive model
In this model of chemically-induced hepatotoxicity, rats were
randomly divided into 6 groups of 6 rats each such that the weight
differences within and between groups did not exceed± 20%. Group
I rats consist of rats pretreated with 10 ml/kg of 0.9% normal saline
while rats in Group IIeVI were orally pretreated on daily basis with
10 ml/kg of 0.9% normal saline, 10 mg/kg of ascorbic acid, 125mg/kg
of MIASE, 250 mg/kg of MIASE, 500 mg/kg of MIASE, respectively, all
dissolved in 0.9% normal saline and pretreated for 7 days. Twenty-
four hours after the last oral pretreatment with ascorbic acid and
graded dose of MIASE, rats were treated with single intraperitoneal
injection of 3 ml/kg of 30% CCl4 dissolved in olive oil. Ascorbic acid,
being a known potent antioxidant, hepatoprotectant was used as a
standard reference drug. Treated rats were then sacriﬁced humanely
forty-eight hours post-CCl4 treatment.
Induction of CCl4-induced hepatotoxicity and oral drug treatment in
the curative model
In thismodel of chemically-induced hepatotoxicity, rats were also
randomly divided into 6 groups of 6 rats each such that the weight
differenceswithin and between groups did not exceed± 20%. Group I
rats consist of rats pretreated with 1 ml/kg of 0.9% normal saline
given intraperitoneally while Groups IIeVI rats were intraperitone-
ally treated on daily basis with 3 ml/kg of 30% CCl4 1 hour before oral
treatment with 10 mg/kg of ascorbic acid, 125mg/kg of MIASE,
250 mg/kg of MIASE, 500 mg/kg of MIASE, respectively, all dissolved
in 0.9% normal saline. All treatment lasted 7 days. Twenty-four hours
after the last treatment, the rats were sacriﬁced humanely under
diethyl ether anesthesia. Again, ascorbic acid, being a known potent
antioxidant, hepatoprotectantwas used as a standard reference drug.
Collection of blood samples
Prior to the termination of the studies, rat feed was withdrawn
in order to fast the rats and their beddings changed. However,
drinking water was provided ad libitum. On the termination day,
rats were anesthetized using inhalational diethyl ether after whichblood samples for hepatic function tests were obtained directly
from the heart chamber using a 21G needle mounted on a 5 ml
syringe plunger and collected into plain sample bottle.
Collection of livers for hepatic tissue oxidative stress markers
After blood collection through cardiac puncture, a deep longi-
tudinal incision was made into the ventral surface of the rat
abdomen. The livers were identiﬁed and carefully dissected out en
bloc from each rat. The right lobe of the liver was rinsed in ice cold
1.15% KCl solution in order to preserve the oxidative enzyme ac-
tivities of the liver before being stored in a clean sample bottle
which itself was in an ice-pack ﬁlled cooler. This is to prevent the
breakdown of the hepatic antioxidant biomarkers.
Determination of liver and renal tissue superoxide dismutase
activity
Superoxide dismutase activity was determined by its ability to
inhibit the auto-oxidation of epinephrine by the increase in
absorbance at 480 nm as described by Sun and Zigman.23 The re-
action mixture (3 ml) contained 2.95 ml 0.05 M sodium carbonate
buffer pH 10.2, 0.02 ml of liver homogenates, and 0.03 ml of
epinephrine in 0.005 N HCl was used to initiate the reaction. The
reference curette contained 2.95 ml buffer, 0.03 ml of substrate
(epinephrine), and 0.02 ml of water. Enzyme activity was calculated
by measuring the change in absorbance at 480 nm for 5 minutes.
Determination of liver tissue catalase activity
Hepatic tissue catalase activity was determined according to
Kakkar et al.24 by measuring the decrease in absorbance at 240 nm
due to the decomposition of H2O2 in UV recording spectropho-
tometer. The reaction mixture (3 ml) contained 0.1 ml of serum in
phosphate buffer (50 mM, pH 7.0) and 2.9 ml of 30 mM of H2O2 in
the phosphate buffer pH 7.0. An extinction coefﬁcient for H2O2 at
240 nm of 40.0 M1 cm1 according to Aebi25 was used for calcu-
lation. The speciﬁc activity of catalase was expressed as moles of
H2O2 reduced per minutes per mg protein.
Determination of liver tissue reduced glutathione activity
The reduced glutathione (GSH) content in the liver tissue was
estimated according to the method described by Sedlak and Lind-
say.26 To the homogenate 10% TCAwas added and centrifuged. One
milliliter of the supernatant was treated with 0.5 ml of Ellman’s
reagent (19.8 mg of 5,5-dithiobisnitro benzoic acid (DTNB) in
100 ml of 0.1% sodium nitrate) and 3.0 ml of phosphate buffer
(0.2 M, pH 8.0). The absorbance was read at 412 nm.
Determination of liver tissue malondialdehyde activity
Malondialdehyde (MDA) an index of lipid peroxidation was
determined using the method of Buege and Aust.27 One milliliter of
supernatant was added to 2 ml of (1:1:1 ratio) TCA-TBA-HCl re-
agent (thiobarbituric acid 0.37%, 0.24 N HCl and 15% TCA) tricar-
boxylic acid, thiobarbituric acid, reagent boiled at 100 C for 15
minutes, and allowed to cool. Flocculent material was removed by
centrifuging at 3000 rpm for ten minutes. The supernatant was
removed and the absorbance was read at 532 nm against a blank.
MDA was calculated using the molar extinction for MDATBA-
complex of 1.56105 m1 cm1.
Determination of serum hepatic function parameters
Serum aspartate transaminase and alanine transaminase
determination
The method of Reitman and Frankel28 was used. Into a test tube,
0.1 ml substrate (D, L-aspartate, 0.2 mol/L and a-ketoglutaric acid,
Table 1
Sequence and results of the limit dose test of MIASE in young female Wistar rats.
Test
sequence
Dose
(mg/kg)
Short-term
result (48 h)
Long-term
result (12 days)
01 5000 Survival Survival
02 5000 Survival Survival
03 5000 Survival Survival
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placed in a 37 C water bath to warm 0.2 ml plasma was added and
shaken gently to mix. Exactly one hour after adding plasma, 1.0 ml
color reagent.
[2, 4-dinitrophenylhydrazine (DNPH) approximately 20 mg/
100 ml, in 10% HCl solution] was added andmixed gently and left at
room temperature (18e26 C). Twenty minutes after adding color
reagent, 10 ml 0.40 N sodium hydroxide solution was added and
mixed by inversion. Five minutes after, absorbance was read at
340 nm using water as reference. AST activity in Sigma-Frankel
units/ml was determined from calibration curve. The same proce-
dure was carried out for ALT except that procedures were started 30
minutes after starting AST. Substrate for ALT was L-alanine
(0.2 mol/L) and a-ketoglutaric acid (1.8 mmol/L) in phosphate
buffer, pH 7.5.28
Serum alkaline phosphatase determination
Alkaline phosphate was determined using the colorimetric end-
point method of Tietz et al. 29 and adapted by Teco Diagnostics Kits.
The principle is based on the fact that alkaline phosphatase acts
upon the AMP-buffered sodium thymolphthalein monophosphate.
The addition of an alkaline reagent stops enzyme activity and
simultaneously develops a blue chorogem, which is measured
photometrically. For each sample 0.5 ml of alkaline phosphatase
substrate was dispensed into labeled test tubes and equilibrated to
37 C for 3 minutes. At timed intervals 0.5 ml of standard, control
and sample were added to their respective test-tube and mixed
gently deionized water was used as blank. The samples were
incubated for exactly ten minutes at 37 C following the same se-
quences, 2.5 ml of alkaline phosphatase color developer at timed
intervals were added. The wavelength of the spectrometer was set
at 590 nm.
Determination of serum lipids, albumin, proteins and fasting blood
glucose
Serum total protein was estimated by Biuret method30 while
that of albumin was determined by bromocresol green.31 The total
bilirubin and the conjugated bilirubin were determined by Jen-
drassikeGrof method.32 The serum total cholesterol and its frac-
tions were determined by the LierbermaneBurchard quantitative
test.33 Fasting blood glucose was determined by glucose oxidase
method of Trinder,34 using One Touch Basic Blood Glucose Moni-
toring System (LifeScan Inc., Milpitas, California, U.S.A.).
Histopathology of the treated rat livers
The remaining part of the liver harvested is gently but briskly
rinsed in 0.9% normal saline and ﬁxed in 10% formo-saline before
being completely dehydrated in absolute (100%) ethanol. The liver
was then embedded in routine parafﬁn blocks. From the embedded
parafﬁn blocks, 4e5 mm thick sections of each tissue was prepared
and stained with hematoxylin-eosin. These were examined under a
photomicroscope (Model N-400ME, CELTECH Diagnostics,
Hamburg, Germany) connected with a host computer. Sections
were illuminated with white light from a 12V halogen lamp
(100 W) after ﬁltering with a 520 nm monochromatic ﬁlter. The
slides were examined for associated histopathological lesions.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Graph
Pad Software e Version 5.0. Graph Pad Software Inc., La Jolla, Cal-
ifornia, U.S.A.). Data were expressed as mean± S.D. for body
weights and relative kidney weights and mean± S.E.M. for
biochemical and hematological assays. The data were analyzed
using the one-way ANOVA for comparison between the control andtreated groups and post hoc test conducted using Newman-Keuls'-
test. Level of statistical signiﬁcance was considered at p< 0.05,
p< 0.001 and p< 0.0001.
Results
Extraction and phytochemical screening of MIASE
Aqueous extraction of pulverized stem bark of Mangifera indica
L. (芒果Mang Guǒ) and its complete drying off yielded a chocolate-
color, sweet-smelling solid residue with a yield of 15%. Preliminary
qualitative phytochemical screening of MIASE for its secondary
metabolites showed that the extract contains alkaloids, tannins,
cardiac glycosides, ﬂavonoids, phlobatinnins, reducing sugars and
saponins with anthocyanosides and anthraquinones being absent.
Acute oral toxicity test of MIASE
Single oral treatment of sequentially treated young adult, nullip-
arous, non-pregnant female Wistar rats with 5000 mg/kg of MIASE
resulted in no mortality and fatality as the short-term and delayed-
term outcome of the oral toxicity test (Table 1). However, behav-
ioral toxicitiesmanifested by the treated rats include body scratching,
feed refusal, reduced locomotor activity, and watery stooling.
Effect of 125e500 mg/kg of MIASE on FBG levels and %DFBG in the
chemopreventive and chemocurative models of CCl4-treated rats
Intraperitoneal injection of CCl4 caused signiﬁcant (p< 0.001)
increases in the FBG levels when compared to untreated normal
rats (Table 2). With oral pre-treatment with 125e500 mg/kg/day of
MIASE, there were signiﬁcant (p< 0.05, p< 0.001 and p< 0.0001)
dose-dependent decreases in the FBG when compared to the un-
treated CCl4-treated (Group II) values (Table 2). In the chemo-
curative model, intraperitoneal injection of CCl4 caused signiﬁcant
(p< 0.05) decreases in the FBG levels when compared to untreated
normal rats (Table 3). However, with post-CCl4 oral treatment with
125e500 mg/kg/day of MIASE, there non-signiﬁcant decreases in
the FBG valuewhen compared to the untreated CCl4-treated (Group
II) values (Table 3).
Effect of 125e500 mg/kg of MIASE on the liver function parameters
in the CCl4-chemopreventive and chemocurative rats
Oral pre-treatment with 125, 250 and 500 mg/kg/day of MIASE
before induction of hepatotoxicity with 3 ml/kg of 30% CCl4 as
measured by the effects of MIASE on liver function parameters (ALT,
AST, ALP, TB, CB) as depicted in Tables 4a and b. Oral pretreatments
with 125e500 mg/kg of MIASE signiﬁcantly (p< 0.001) attenuated
increases in the serum ALT, AST, ALP, TB and CB levels when
compared to untreated CCl4-treated rats (Table 4a). Similarly,
125e500 mg/kg of MIASE signiﬁcantly (p< 0.05, p< 0.001,
p< 0.0001) attenuated decreases in and improved the serum TP,
ALB, TG, TC and HDL-c levels when compared to that of untreated
CCl4-treated rats (Group II) values (Table 4b). Although intraperi-
toneal CCl4 treatment caused no signiﬁcant (p> 0.05) alterations in
Table 2
Effects of oral pretreatments of 125e500 mg/kg of MIASE on the fasting blood
glucose concentration (FBG) (mg/dl) and %D FBG of CCl4-treated rats.
Groups FBG (mg/dl) on
Day 1 Day 8 %D FBG
I 57.67± 3.03 55.83± 1.76 5.33± 2.87
II 59.83± 3.04 65.33± 1.45b 8.33± 4.61
III 56.00± 3.52 45.67± 3.29f -29.47± 12.71f
IV 59.50± 3.35 53.00± 1.73f -11.73± 4.43d
V 53.17± 3.15 45.33± 1.76f -18.61± 7.14e
VI 54.00± 3.79 41.50± 1.80f -33.76± 8.37f
b represents a signiﬁcant increase at p< 0.001 when compared to Group I values
while d, e and f represent signiﬁcant decreases at p< 0.05, p< 0.001 and p< 0.0001
when compared to Group II values, respectively.
Table 3
Effects of oral pretreatments of 125e500 mg/kg of MIASE on the fasting blood
glucose concentration (FBG) (mg/dl) and %D FBG of CCl4-chemocurative rats.
Groups FBG (mg/dl) on
Day 1 Day 8 %D FBG
I 55.50± 0.96 55.50± 0.85 0.06± 1.90
II 59.33± 1.45 42.00± 1.77a -29.13± 2.95b
III 58.17± 0.75 48.83± 2.52 -15.79± 5.14
IV 58.50± 0.76 52.50± 4.06 -10.60± 5.88
V 59.83± 1.49 48.83± 3.54 -18.29± 6.05a
VI 58.67± 1.17 41.67± 2.40a -28.89± 4.26b
a and b represent signiﬁcant decreases at p< 0.05 and p< 0.001 when compared
to Group I values, respectively.
Table 5a
Effect of post-CCl4 oral treatments with 125e500 mg/kg/day of MIASE on serum ALT,
AST, ALP, TB and CB in the CCl4-treated rats.
Groups ALT (IU/L) AST (IU/L) ALP (IU/L) TB (mg/dl) CB (mg/dl)
I 15.50± 0.76 36.00± 2.24 27.70± 1.81 1.29± 0.07 0.24± 0.00
II 54.83± 2.65c 97.83± 2.69c 69.13± 3.81c 1.98± 0.04c 1.39± 0.06c
III 15.00± 1.37f 21.17± 2.20e 41.73± 1.86f 1.18± 0.11f 0.30± 0.01f
IV 23.17± 1.28e 64.33± 1.61e 51.37± 4.54e 1.58± 0.10e 0.30± 0.01f
V 15.50± 0.76f 50.67± 4.49f 41.70± 3.17f 1.16± 0.12f 0.28± 0.02f
VI 12.67± 0.71f 42.67± 2.62f 32.72± 2.10f 1.21± 0.07f 0.29± 0.02f
c represents a signiﬁcant increase at p< 0.0001 when compared to Group I values
while e and f represent signiﬁcant decreases at p< 0.001 and p< 0.0001, respec-
tively, when compared to Group II values.
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treated control (Group I), however, oral treatment with
125e500 mg/kg of MIASE caused dose-related signiﬁcant
(p< 0.001) decreases in the serum LDL-c levels when compared to
untreated CCl4-treated rats (Table 4b).
Oral treatment with 125, 250 and 500 mg/kg/day of MIASE 1
hour post-CCl4 treatment with 3 ml/kg of 30% CCl4 as measured by
their effects on liver function parameters (ALT, AST, ALP, TB, CB)
signiﬁcantly (p< 0.001 and p< 0.0001) attenuated increases in the
levels of these liver function parameters (Table 5a). Similarly,
125e500 mg/kg of MIASE signiﬁcantly (p< 0.05, p< 0.0001)Table 4a
Effect of oral pretreatments with 125e500 mg/kg/day of MIASE on serum ALT, AST, ALP,
Groups ALT (IU/L) AST (IU/L)
I 29.83± 1.72 20.67± 2.82
II 87.00± 2.41c 65.33± 3.71c
III 36.33± 3.73e 21.17± 2.20e
IV 79.17± 4.95 47.83± 2.41d
V 36.50± 4.95e 18.00± 2.34f
VI 23.80± 1.28f 14.83± 1.17f
c represents a signiﬁcant increase at p< 0.0001 when compared to Group I values wh
respectively, when compared to Group II values.
Table 4b
Effect of oral pretreatments with 125e500 mg/kg/day of MIASE on serum ALT, TP, ALB, T
Groups TP (g/dl) ALB (g/dl) TG (mmol/l)
I 68.47± 1.74 46.55± 0.95 1.28± 0.07
II 39.33± 1.58c 21.04± 1.06c 0.50± 0.06c
III 67.10± 1.91cþ 14.10± 1.78aþ 0.97± 0.05
IV 58.44± 3.46aþ 42.75± 2.27cþ 0.76± 0.15
V 62.85± 3.02aþ 43.64± 1.79 0.93± 0.14
VI 69.85± 0.51cþ 43.81± 0.55cþ 1.23± 0.11cþ
c represents a signiﬁcant decrease at p< 0.0001 when compared to Group I values whi
respectively, when compared to Group II values; f represents signiﬁcant a decreases at pattenuated decreases in and improved the serum TP, ALB, TG, TC,
HDL-c, and LDL-c levels when compared to that of untreated CCl4-
treated rats (Group II) values (Table 5b).Effect of 125e500 mg/kg of MIASE on the tissue antioxidant status in
the CCl4-chemopreventive and chemocurative rats
Table 6 shows the effects of oral pre-treatments with
125e500 mg/kg/day of MIASE and subsequent intraperitoneal CCl4
treatment on the antioxidant markers (SOD, CAT, GSH and MAD) in
the treated rats. CCl4 treatment caused signiﬁcant (p< 0.05 and
p< 0.001) decreases in the hepatic tissue SOD, CAT and GSH while
causing signiﬁcant (p< 0.001 and p< 0.0001) increases in the he-
patic and renal tissue MAD (Table 6). Oral pretreatment with 250
and 500 mg/kg of MIASE signiﬁcantly (p< 0.05 and p< 0.0001)
attenuated decreases in the hepatic tissue levels of SOD, CAT and
GSH levels while signiﬁcantly attenuated increases in the hepatic
tissue MAD levels (Table 6). These effects were comparable to that
recorded for the 10 mg/kg of the standard antioxidant (ascorbic
acid) used. However, 125 mg/kg/day of MIASE did cause signiﬁcant
(p> 0.05) alterations in the hepatic tissue SOD, CAT, GSH and MAD
levels when compared to that of the untreated CCl4-treated (Group
II) rats (Table 6). Similarly, Table 7 shows the effects of
125e500 mg/kg of MIASE on hepatic tissue antioxidant markers
(SOD, CAT, GSH and MAD) in the post-CCl4 treated rats. CCl4
treatment caused signiﬁcant (p< 0.05 and p< 0.0001) decreases onTB and CB in the CCl4-treated rats.
ALP (IU/L) TB (mg/dl) CB (mg/dl)
77.41± 6.63 8.68± 0.45 2.43± 0.37
162.30± 10.29c 20.02± 0.36c 12.75± 0.36c
98.72± 14.03d 14.10± 1.78d 3.78± 0.34e
92.27± 1.14d 9.90± 0.78e 11.62± 0.55cþ
61.50± 5.28e 9.43± 0.34e 2.68± 0.27f
69.85± 0.51f 10.39± 0.37e 2.88± 0.28f
ile d, e and f represent signiﬁcant decreases at p< 0.05, p< 0.001 and p< 0.0001,
G, TC, HDL-c and LDL-c in the CCl4-treated rats.
TC (mmol/l) HDL-c (mmol/l) LDL-c (mmol/l)
3.09± 0.20 1.43± 0.11 1.27± 0.17
2.02± 0.11c 0.50± 0.0c 1.03± 0.05
2.94± 0.23bþ 1.21± 0.08cþ 1.30± 0.05
2.65± 0.11aþ 1.72± 0.10cþ 0.55± 0.17f
2.67± 0.06cþ 1.80± 0.06cþ 0.53± 0.09f
3.01± 0.17bþ 1.59± 0.11cþ 0.46± 0.18f
le aþ, bþ and cþ represent signiﬁcant increases at p< 0.05, p< 0.001 and p< 0.0001,
< 0.0001 decreases when compared to Group II values.
Table 5b
Effect of post-CCl4 oral treatments with 125e500 mg/kg/day of MIASE on serum ALT, TP, ALB, TG, TC, HDL-c and LDL-c in the CCl4-treated rats.
Groups TP (g/dl) ALB (g/dl) TG (mmol/l) TC (mmol/l) HDL-c (mmol/l) LDL-c (mmol/l)
I 78.54± 2.35 46.03± 0.63 0.77± 0.05 2.56± 0.07 1.67± 0.06 0.59± 0.09
II 40.42± 0.31c 25.37± 1.03c 0.44± 0.03c 1.46± 0.14c 1.16± 0.07c 1.16± 0.07c
III 77.54± 1.51cþ 44.80± 0.76aþ 0.68± 0.04aþ 1.87± 0.06aþ 1.15± 0.03 0.51± 0.05f
IV 59.25± 2.85bþ 35.27± 0.49 0.86± 0.05aþ 1.65± 0.09 0.93± 0.12 0.35± 0.06f
V 78.24± 1.10cþ 46.22± 0.70cþ 1.12± 0.15cþ 1.49± 0.12 0.95± 0.07 0.30± 0.03f
VI 81.62± 2.43cþ 56.75± 0.66cþ 1.69± 0.02cþ 1.85± 0.02 1.61± 0.02aþ 0.05± 0.01f
c and c represent signiﬁcant decreases and increases at p< 0.0001, respectively when compared to Group I values while aþ, bþ and cþ represent signiﬁcant increases at p< 0.05,
p< 0.001 and p< 0.0001, respectively, when compared to Group II values. f represents signiﬁcant decreases at p< 0.001 when compared to Group II values.
Table 6
Effect of pre-CCl4 oral treatments with 125e500 mg/kg/day of MIASE on hepatic
tissue SOD, CAT, GSH and MDA in the CCl4-treated rats.
Group SOD
(U/mg protein)
CAT
(U/mg protein)
GSH
(U/mg protein)
MDA
(U/mg protein)
I 4.04± 0.52 23.48± 2.77 2.08± 0.22 0.16± 0.03
II 2.29± 0.29a 13.42± 0.92b 1.25± 0.09 0.38± 0.10b
III 3.14± 0.36 16.53± 0.32 1.78± 0.16 0.08± 0.02f
IV 3.47± 0.30 17.66± 1.08 1.77± 0.32 0.13± 0.01e
V 4.83± 0.22cþ 27.79± 2.01cþ 3.12± 0.30cþ 0.11± 0.02e
VI 5.69± 0.45cþ 35.18± 1.69cþ 4.51± 0.23cþ 0.04± 0.01f
a and b represent signiﬁcant decreases at p< 0.05 and p< 0.001, respectively,
when compared to Group I values while bþ and cþ represent signiﬁcant increases at
p< 0.001 and p< 0.0001, respectively, when compared to Group II values. b repre-
sents a signiﬁcant increase at p< 0.001 when compared to Group II values while e
and f represent signiﬁcant decreases at p< 0.001 and p< 0.0001, respectively, when
compared to Group II values.
Fig. 1. A sectional representative of normal rat liver showing normal hepatic archi-
tecture (Hematoxylin & Eosin, x100 magniﬁcation).
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(p< 0.001 and p< 0.0001) increases in the hepatic and renal MAD
values (Table 7). However, post-CCl4 oral treatments with
125e500 mg/kg/day of MIASE signiﬁcantly (p< 0.05, p< 0.001 and
p< 0.0001) reversed and improved the values of these markers
when compared to values for the untreated CCl4-treated rats and
returning them to near normal values (Table 7).Histopathological evaluation
Figs. 1e6 are the photomicrographs of the lesions induced by
CCl4-treatment and pre-CCl4 oral treatments with 125e500 mg/kg/
day of MIASE on the treated rat livers. Intraperitoneal CCl4 injection
was marked by hepatic centrilobular vacuolation and vascular
congestion indicative of early hepatic necrosis (Fig. 2) when
compared to normal hepatic architecture (Fig. 1). However, oral
pretreatments with 10 mg/kg/day of vitamin C and 125e500 mg/
kg/day of MIASE for 7 days caused amelioration of the CCl4-inducedTable 7
Effect of oral treatments with 125e500 mg/kg/day of MIASE on hepatic tissue SOD,
CAT, GSH and MDA in post-CCl4-treated rats.
Group SOD
(U/mg protein)
CAT
(U/mg protein)
GSH
(U/mg protein)
MDA
(U/mg protein)
I 2.74± 0.19 24.84± 1.66 0.92± 0.07 0.10± 0.00
II 1.59± 0.17c 11.29± 0.63c 0.48± 0.03a 0.15± 0.03b
III 3.68± 0.26cþ 27.50± 1.87cþ 1.72± 0.06cþ 0.02± 0.01f
IV 3.68± 0.26cþ 18.24± 1.21bþ 0.99± 0.20aþ 0.09± 0.01e
V 3.92± 0.22cþ 20.71± 1.15cþ 1.25± 0.19cþ 0.11± 0.01
VI 4.07± 0.12cþ 26.45± 1.50cþ 1.72± 0.05cþ 0.08± 0.01e
a and c represent signiﬁcant decreases at p< 0.05 and p< 0.0001, respectively,
when compared to Group I values while aþ, bþ and cþ represent signiﬁcant increases
at p< 0.05, p< 0.001 and p< 0.0001, respectively, when compared to Group II
values. b represents a signiﬁcant increase at p< 0.001 when compared to Group II
values while e and f represent signiﬁcant decreases at p< 0.001 and p< 0.0001,
respectively, when compared to Group II values.histological lesions of hepatic necrosis (Figs. 3e6). Similarly,
Figs. 7e11 show the histopathological ﬁndings of post-CCl4 oral
pretreatments with 125e500 mg/kg/day of MIASE on the liver
tissue of CCl4-treated rats. Single intraperitoneal treatment with
CCl4 caused marked vascular congestion with ballooning and
vacuolation of periportal hepatocytes and hepatocytes around the
central hepatic vein (Fig. 7) when compared to normal hepatic ar-
chitecture (Fig. 1). With repeated daily oral pretreatments with
10 mg/kg of vitamin C and 125e500 mg/kg/day of MIASE, theseFig. 2. A sectional representative of untreated CCl4-treated rat liver showing hepato-
cyte ballooning and hepatic centrilobular necrosis and vascular congestion indicating
early hepatic necrosis (Hematoxylin & Eosin stain, x400 magniﬁcation).
Fig. 3. A sectional representative of rat liver pretreated with 10 mg/kg/day of vitamin C
before intraperitoneal CCl4 treatment showing focal hepatocyte vacuolation and cen-
tral venous congestion (Hematoxylin & Eosin stain, x400 magniﬁcation).
Fig. 5. A sectional representative of rat liver pretreated with 250 mg/kg/day of MIASE
before CCl4 intraperitoneal treatment showing moderate focal centrilobular hepato-
cyte vacuolation and mild central venous congestion (Hematoxylin & Eosin stain, x400
magniﬁcation).
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(Figs. 9e11).Discussion
The liver, as the key organ of drug metabolism and excretion, is
naturally endowed with the major task of drug detoxiﬁcation.
Hepatotoxicants including viruses, fungal products, bacterial me-
tabolites, minerals, environmental pollutants and chemothera-
peutic agents can induce various and varying degrees of injury to
the liver.35 CCl4-induced hepatic injury is a classical and reliable
model of xenobiotic-induced hepatotoxicity that has been exten-
sively used for the screening of drugs for their possible anti-
hepatotoxic/hepatoprotective activity.36
In the present study, the preventive and curative hep-
atoprotective effects of MIASE against CCl4-induced hepatotoxicityFig. 4. A sectional representative of pretreated with 125 mg/kg/day of MIASE before
CCl4 intraperitoneal treatment showing global moderate-to-severe hepatocyte vacu-
olation and severe central venous congestion (Hematoxylin & Eosin stain, x400
magniﬁcation).
Fig. 6. A representative section of rat liver pretreated with 500 mg/kg/day of MIASE
before CCl4 treatment showing hepatic sinusoid congestion and mild central venous
congestion with normal hepatocytes (Hematoxylin & Eosin stain, x400 magniﬁcation).
Fig. 7. A sectional representative of untreated CCl4-treated rat liver showing marked
vascular congestion with ballooning and vacuolation of periportal hepatocytes and
hepatocytes around the central hepatic vein (Hematoxylin & Eosin, x100
magniﬁcation).
Fig. 8. A sectional representative of post-CCl4 treated rat liver treated with 10 mg/kg/
day of vitamin C showing moderate hepatic vascular congestion (Hematoxylin & Eosin,
x100 magniﬁcation).
Fig. 10. A sectional representative of CCl4-treated rat liver pretreated with 250 mg/kg/
day of MIASE showing mild congested hepatic vascular channels and patchy hepatic
vacuolation (Hematoxylin & Eosin, x100 magniﬁcation).
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signiﬁcant increases in the serum ALT, AST, ALP, TB and CB levels
with concomitant signiﬁcant decreases in the TP, ALB, TC, HDL-c
and LDL-c levels. Signiﬁcant serum elevations in these hepatic
biochemical markers have been attributed to the compromised
structural and functional integrity of the hepatocytes.37 Both pre-
ventive and curative oral treatments with 125e500 mg/kg/day of
MIASE for 7 days signiﬁcantly reversed the altered serum liver
function parameters in the CCl4-treated rats with more signiﬁcant
hepatoprotective effect offered in the curative treatment. Results of
this present study on the hepatoprotective activity of MIASE is in
line with that earlier reported for the lupeol and mango pulp
extract in carcinogen-induced hepatotoxicity in Swiss Albino mice
despite differences in the doses, plant parts, and animal models
studied.38 Again, the fact that MIASE signiﬁcantly reversed the
deleterious effect of CCl4 serum lipids is a strong indication of the
anti-atherogenic potential of MIASE which lends support to the
earlier report on the antihyperglycemic and anti-atherogenicity of
mangiferin in streptozotocin diabetic rats.39 In the same vein,
intraperitoneal treatment with CCl4 elicited hyperglycemia which
was signiﬁcantly (p< 0.05, p< 0.001 and p< 0.0001) reduced dose-
dependently by oral treatments with 125e500 mg/kg/day of
MIASE. Although, earlier studies have reported CCl4-induced hy-
perglycemia in rats treated with CCl4,37,40,41 the marked reductionFig. 9. A sectional representative of post-CCl4 treated rat liver orally treated with
125 mg/kg/day of MIASE showing marked global vacuolation and patchy necrosis of
hepatocytes around congested hepatic vascular channels (Hematoxylin & Eosin, x100
magniﬁcation).in FBG values, suggests the antihyperglycemic potential of MIASE in
CCl4-induced hyperglycemia in rats. Although several studies have
independently reported the antihyperglycemic effect of MIASE in
different diabetic rat models,3,4,42 this study reports for the ﬁrst
time the hypoglycemic effect of MIASE in the CCl4-induced hepa-
totoxic rats.
CCl4, as a potent chemical hepatotoxin, is widely used for the
induction of experimental hepatotoxicity in animal models. CCl4
after its administration undergoes reductive metabolism by the
hepatic CYP2E1 into a highly reactive trichloromethyl radical (CCl3-)
that initiates lipid peroxidation, disrupts membrane integrity and
causes hepatocyte necrosis and death.43 In all of these, the role of
oxidative stress in the etiopathogenesis of hepatic disorders is well
documented.44 The free radicals generated as a result of reductive
halogenation of CCl4, in the presence of oxygen, lead to auto-
oxidation of free fatty acids and cause functional and morpholog-
ical alterations in the hepatocyte cell membrane after binding
covalently to membrane lipids and proteins, or abstracting a
hydrogen atom from and unsaturated lipid and initiating lipid
peroxidation.43,45 Thus, prevention and/or inhibition of free radical
generation and promotion of antioxidant activity constitute
important defense system against CCl4-induced hepatic injury.46,47
In measuring free radicals-induced oxidative stress, enzyme
markers such superoxide dismutase (SOD), catalase (CAT), reducedFig. 11. A sectional representative of post-CCl4 treated rat liver treated with 500 mg/
kg/day of MIASE showing mild congested hepatic vascular channels (Hematoxylin &
Eosin, x100 magniﬁcation).
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malondialdehyde (MAD), are widely accepted and used.48
In order to evaluate the effect of MIASE on CCl4-induced
oxidative stress, hepatic tissue levels of GSH and activities of anti-
oxidant enzymes CAT, SOD, and MAD were measured. Adminis-
tration of CCl4 by intraperitoneal route profoundly elevated the
tissue activities of these antioxidant enzymes while signiﬁcantly
decreasing the hepatic tissue GSH concentration. Accompanying
these biochemical changes are histological changes of hepatocyte
vacuolation/ballooning and hepatic centrilobular necrosis. These
biochemical and histopathological results are in strong consonance
with the earlier ﬁndings of Brattin et al.,49 Fukao et al.50 and Padhy
et al.51 However, daily oral treatment with 125e500 mg/kg/day of
MIASE over 7 days afforded hepatoprotection dose-dependently
with better protection offered by MIASE administered curatively
than that offered prophylactically. In addition, MIASE administered
post-CCl4 treatment produced marked dose-related reductions in
the hepatic MAD level, MAD being a reliable index of lipid peroxi-
dation. Thus, this results strongly further suggests anti-
lipoperoxidation activity of MIASE. The antioxidant and anti-
lipoperoxidative properties of MIASE could be attributed to its
constituent ﬂavonoids and other polyphenolics as these phyto-
components have been widely reported to possess antioxidant and
anti-lipoperoxidative activities.52,53 Preliminary qualitative phyto-
chemical screening of MIASE for its secondary metabolites showed
that the extract contains alkaloids, tannins, cardiac glycosides, ﬂa-
vonoids, phlobatinnins, reducing sugars and saponins with
anthocyanosides and anthraquinones being absent. This is in
complete agreement with other earlier reports.35,36
Conclusion
The present study suggests that MIASE has a potent hep-
atoprotective activity in CCl4-induced hepatic injury in rats. MIASE
may possess both antioxidant and anti-lipoperoxidative activities by
inhibiting and scavenging free radicals generated by CCl4. These
ﬁndings provide biochemical and histological data supporting folk-
loric use of MIASE in the local treatment of some hepatic disorders.
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